The effects of isatin (indole-2, 3-dione) on pituitary adenylate cyclase-activating polypeptide-induced hyperthermia in rats
© Pataki et al; licensee BioMed Central Ltd. 2002
Received: 01 December 2001
Accepted: 20 February 2002
Published: 20 February 2002
Previous studies have demonstrated that centrally administered natriuretic peptides and pituitary adenylate cyclase-activating polypeptide-38 (PACAP-38) have hyperthermic properties. Isatin (indole-2, 3-dione) is an endogenous indole that has previously been found to inhibit hyperthermic effects of natriuretic peptides. In this study the aim was to investigate the effects of isatin on thermoregulatory actions of PACAP-38, in rats.
One μg intracerebroventricular (icv.) injection of PACAP-38 had hyperthermic effect in male, Wistar rats, with an onset of the effect at 2 h and a decline by the 6th h after administration. Intraperitoneal (ip.) injection of different doses of isatin (25-50 mg/kg) significantly decreased the hyperthermic effect of 1 μg PACAP-38 (icv.), whereas 12.5 mg/kg isatin (ip.) had no inhibiting effect. Isatin alone did not modify the body temperature of the animals.
The mechanisms that participate in the mediation of the PACAP-38-induced hyperthermia may be modified by isatin. The capability of isatin to antagonize the hyperthermia induced by all members of the natriuretic peptide family and by PACAP-38 makes it unlikely to be acting directly on receptors for natriuretic peptides or on those for PACAP in these hyperthermic processes.
Pituitary adenylate cyclase-activating polypeptide (PACAP) is known as a member of a superfamily that includes vasoactive intestinal polypeptide (VIP), secretin, glucagon, gastric inhibitory polypeptide and growth hormone-releasing factor . The biologically active neuropeptide exists in two amidated forms: PACAP-38, a 38-amino-acid polypeptide; and PACAP-27, a truncated form of PACAP-38 containing 27 residues . Both PACAP-38 and PACAP-27 are potent in stimulating adenylate cyclase.
At least two receptor classes have been reported for PACAP in mammalian tissues: type I and type II. Type I receptors are highly selective in the recognition of PACAP, and have lower affinity for VIP. Type II receptors display similar high affinity for PACAP-27, PACAP-38 and VIP . Type II (VIP-PACAP) receptors interact almost exclusively with adenylate cyclase. At least two effector systems exist for type I PACAP-preferring receptors, which can stimulate both adenylate cyclase and phospholipase C. Subsequent to phospholipase C activation via the inositol phosphate cascade, a secondary Ca2+ entry elevating cytosolic [Ca2+] follows Ca2+ mobilization .
Recent investigations carried out in our laboratory demonstrated that PACAP-38  induced dose-dependent elevations in the body temperature of rats when injected centrally. Different members of the natriuretic peptide family had a similar effect . The natriuretic peptides-induced hyperthermia was abolished by the endogenous indole isatin (indole-2, 3-dione) . Isatin has been found to act as an antagonist at natriuretic peptide receptors of the brain and heart, and it may well be that isatin is an endogenous inhibitor of these peptides at a central level . Although the antagonism by isatin of some of the behavioral effects of ANP has been described , much remains to be understood concerning the interaction of isatin and neuropeptide systems.
The present study was carried out to investigate the effects of isatin on PACAP-38- induced hyperthermia.
Effects of isatin on the PACAP-38-induced hyperthermia
We have previously demonstrated that central administration of PACAP-38 produces a long lasting hyperthermia in rats, raising the possibility that this neuropeptide plays a part in thermoregulatory processes at a central level. No effect of the peptide on body temperature is seen 24 h after injection . Other results provided evidence that the endogenous indole isatin inhibited the hyperthermia induced by natriuretic peptides .
The effects of isatin on PACAP-38-induced hyperthermia were investigated in this study. Injections of PACAP-38 into the lateral ventricle of the brain elevated the body temperature of the experimental animals with an onset of the hyperthermia at 2 h and a decline at 6 h. Single injections of isatin doses after the onset of the peptide-induced hyperthermia diminished the hyperthermic effect of PACAP-38 whereas isatin itself did not modify the body temperature. A positive correlation was observed between the antihyperthermic effect and the dose of isatin administered. No effect of the indole on hyperthermia was shown 2.5 h after injection.
An unpublished pilot study in our laboratory indicated that isatin did not have noticeable effect on the hyperthermia induced by PACAP-38 when injected before the onset of the body temperature elevation. This accounted for the isatin treatment 3.5 h after PACAP injection but does not support a possible interaction between PACAP receptors and the indole in the antihyperthermic effect of isatin.
The present results demonstrate that isatin is able to diminish the hyperthermic effect of neuropeptides other than natriuretic peptides, namely that of PACAP-38. The capability of isatin to antagonize the hyperthermia induced by all members of the natriuretic peptide family and also by PACAP-38 raises the possibility of common pathways in the mediation of these neuropeptide-induced hyperthermic actions. However the hyperthermias induced by natriuretic peptides display earlier onset and shorter duration than that induced by PACAP-38. This makes it unlikely that isatin acts directly on receptors of natriuretic peptides or on those of PACAP in these hyperthermic processes. Moreover it does not support a possible action of the indole on an uncharacterized target that links the actions of natriuretic peptides and PACAP-38 to each other. To our knowledge no data are yet available on central actions of PACAP and natriuretic peptides being interrelated.
The exact mediatory pathway(s) of the PACAP-38-induced hyperthermia has not been clarified. However the involvement of prostaglandin products and possibly interleukins in the mediation are possible . On the basis of our present data the connections of isatin to the interleukin-prostaglandin pathway in hyperthermic events and particularly in the hyperthermic effect of PACAP-38 require further examination.
Our data indicate that the hyperthermic effect of centrally administered PACAP-38 is inhibited by isatin in rats and establishes an in vivo interaction between isatin and PACAP.
Materials and Methods
The animals were kept and treated under a protocol accepted by the Committee on Animal Experiments, University of Szeged, Hungary.
Adult male Wistar rats weighing 200-240 g were used. Each animal was used only once for the experiments. The animals were housed in groups of 5-6 in cages in a room maintained at constant temperature (23 ± 1 °C) and on a standard illumination (lights on from 6 to 18). They had free access to tap water and standard laboratory food. Rats were allowed a minimum of 5 days of recovery from surgery before the beginning of experiments.
In order to allow intracerebroventricular (i.c.v.) peptide administration, the rats were implanted with a unilateral cannula introduced into the right lateral brain ventricle before the experiment. Under pentobarbital (Nembutal, Ceva, France; 35 mg/kg) intraperitoneal (i.p.) anesthesia, the stainless steel cannula was inserted stereotaxically into the ventricle with coordinates 0.2 mm posterior; 1.7 mm lateral to the bregma; 3.7 mm deep from the dural surface, according to the atlas of Pellegrino et al. (1979). The cannula was secured with dental acrylic cement. Rats were allowed a minimum of 5 days to recover from surgery before peptide treatment. Upon the conclusion of the experiments, 10 μl methylene blue was injected into the ventricle of the decapitated animals and the position of the cannula was inspected visually. Animals with improper cannula placement were excluded from the final statistical analysis.
Rat PACAP-38 was purchased from Bachem (Switzerland) or was synthesized by G. Tóth. For i.c.v. treatment, different doses of PACAP-38 were dissolved in sterile pyrogen-free 0.9% saline and injected in a volume of 2 μl. Isatin was administered i.p. in doses of 12.5, 18.75, 25 and 50 mg/kg, diluted in saline in a volume of 2.5 ml/kg. The control groups were treated with saline for all experiments.
On the day of the experiment, the animals were transferred to the laboratory 2 h before the beginning of the test in order for them to habituate to the experimental environment. The room temperature was maintained at 23.0 ± 0.5°C throughout the experiment. Each animal was then removed from the cage and gently restrained with a cloth on the table. The colon temperature was monitored by inserting the vaseline-lubricated thermistor probe of a digital electric thermometer (Model: Cole-Parmer 8402-10) 5 cm into the rectum of the animal. The probe was inserted the same distance into the rectum each time it was used.
The experiments started at 8 a.m. with an initial colon temperature measurement, the colon temperature also being measured before and 1, 2, 3, 4, 5 and 6 h after peptide treatment.
The effects of i.p. administered isatin on the PACAP-38-induced hyperthermia were studied. Different doses (12.5, 18.75, 25, 50 mg/kg) of isatin were given i.p. once 3.5 h after i.c.v. peptide treatment (PACAP-38 being injected in a dose of 1 μg) and the colon temperature was measured 1, 2, 3, 4, 5 and 6 h later.
Statistical analysis of the data was made by analysis of variance (ANOVA). For significant ANOVA values, groups were compared by Tukey's test for multiple comparisons with unequal cell size. A probability level of 0.05 was accepted as indicating significant differences.
This work was supported by grants from OTKA (T-022230), ETT (T-123-04), AKP (2000-114 3.2), MÖB 004 and FKFP (0091-1997).
- Bhattacharya SK, Chakrabarti A, Sandler M, Glover V: Anxiolytic activity of intraventricularly administered atrial natriuretic peptide in the rat. Neuropsychopharmacology. 1996, 15: 199-206. 10.1016/0893-133X(95)00204-Q.View ArticlePubMedGoogle Scholar
- Harmar AJ, Arimura A, Gozes I, Journot L, Laburthe M, Pisegna JR, Rawlings SR, Robberecht P, Said SI, Sreedharan SP, Wank SA, Waschek JA: International Union of Pharmacology. XVIII. Nomenclature of Receptors for Vasoactive Intestinal Peptide and Pituitary Adenylate Cyclase-Activating Polypeptide. Pharmacol Rev. 1998, 50: 265-270.PubMedGoogle Scholar
- Medvedev AE, Goodwin BL, Sandler M, Glover V: Efficacy of isatin analogues as antagonists of rat brain and heart atrial natriuretic peptide receptors coupled to particulate guanylyl cyclase. Biochem Pharmacol. 1999, 57: 913-915. 10.1016/S0006-2952(98)00371-2.View ArticlePubMedGoogle Scholar
- Miyata A, Jiang L, Dahl RD, Kitada C, Kubo K, Fujino M, Minamino N, Arimura A: Isolation of a neuropeptide corresponding to the N-terminal 27 residues of the pituitary adenylate cyclase activating polypeptide with 38 residues (PACAP38). Biochem Biophys Res Commun. 1990, 170: 643-648.View ArticlePubMedGoogle Scholar
- Pataki I, Adamik Á, Mácsai M, Jászberényi M, Telegdy G: Pituitary adenylate cyclase-activating polypeptide induces hyperthermia in the rat. Neuropharmacology. 2000, 39: 1303-1308. 10.1016/S0028-3908(99)00209-9.View ArticlePubMedGoogle Scholar
- Pataki I, Adamik Á, Telegdy G: Isatin (indole-2, 3-dione) inhibits natriuretic peptide-induced hyperthermia in rats. Peptides. 2000, 21: 373-377. 10.1016/S0196-9781(00)00149-2.View ArticlePubMedGoogle Scholar
- Pataki I, Jászberényi M, Telegdy G: Hyperthermic effect of centrally administered natriuretic peptides in the rat. Peptides. 1999, 20: 193-197. 10.1016/S0196-9781(98)00173-9.View ArticlePubMedGoogle Scholar
- Pellegrino LJ, Pellegrino AS, Cushman AJ: Stereotic atlas of the rat brain. Plenum Press, New York. 1979, 8-57.Google Scholar
- Vaudry D, Gonzalez BJ, Basille M, Yon L, Fournier A, Vaudry H: Pituitary Adenylate Cyclase-Activating Polypeptide and Its Receptors: From Structure to Functions. Pharmacol Rev. 2000, 52: 269-324.PubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article: verbatim copying and redistribution of this article are permitted in all media for any purpose, provided this notice is preserved along with the article's original URL.